Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT01761201 Terminated - Clinical trials for Latent Tuberculosis Infection

"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".

FLISH-ILT
Start date: January 2012
Phase: Phase 3
Study type: Interventional

A multicenter, prospective, non-inferiority, randomized and open clinical trial comparing levofloxacin with isoniazid in the treatment of latent tuberculosis infection in patients eligible for liver transplantation. Patients over 18 years of age on the waiting list for liver transplantation. Sample size: n=870 patients. HYPOTHESIS Levofloxacin treatment of latent tuberculosis infection, begun while on the waiting list for liver transplantation, is safer and not less effective than isoniazid treatment begun after transplantation when liver function is stable.

NCT ID: NCT01760109 Completed - Clinical trials for Urinary Tract Infections

Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

PIP-SBT
Start date: July 2011
Phase: Phase 4
Study type: Interventional

In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.

NCT ID: NCT01758081 Active, not recruiting - Infections Clinical Trials

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

Start date: July 2010
Phase: N/A
Study type: Interventional

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma hCAP18 levels.

NCT ID: NCT01756924 Terminated - Clinical trials for Prosthetic Joint Infections of Hip

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Start date: December 2012
Phase: Phase 2
Study type: Interventional

To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections

NCT ID: NCT01754428 Completed - Clinical trials for Respiratory Syncytial Virus Infections

Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

Start date: November 2012
Phase: N/A
Study type: Observational

The purpose of this study is to collect clinical outcome and nasal viral load information.

NCT ID: NCT01754311 Completed - HTLV-I Infections Clinical Trials

Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1

HAMIL28B
Start date: May 13, 2013
Phase:
Study type: Observational

Only 5 to 10% of patients infected with HTLV-1 develop a disease related to infection. The two most serious diseases are adult T-cell leukemia (ATL) and Tropical spastic paraparesis /HTLV-I-associated myelopathy (TSP / HAM). Factors influencing the development of TSP / HAM in the individual HTLV-1 are not yet completely understood. Patients TSP / HAM have a HTLV-1 proviral load (amount of virus) that is 6-10 times higher than seropositive asymptomatic. Various studies have shown that the development of TSP / HAM in the subject HTLV-1 and its rapid evolution is partly attributed to the failure of the immune system that regulates viral replication and expression. It has recently been shown that different versions of Single Nucleotide (human leukocyte antigen) rs12979860, located upstream of the gene for Interleukin 28B (IL28B), influenced the severity of infection with hepatitis C and effectiveness of treatment. By analogy with hepatitis C, a Spanish (Treviño et al., 2012) examined this SNP(single nucleotide polymorphism) in 12 patients TSP / HAM and 29 asymptomatic HIV-positive. CT or TT genotype was statistically more frequent in the group TSP / HAM than in asymptomatic patients (80% versus 20%) and was associated with HTLV-1 proviral load higher. We propose a broader group of patients in our population and Afro-Caribbean, to confirm the results of the latter study was conducted in a predominantly Latin American population.

NCT ID: NCT01746654 Completed - Clinical trials for Bacterial Infections

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

Start date: December 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the antibacterial protein P128 is (i) safe and well tolerated in healthy volunteers and in chronic kidney diseases patients on dialysis, (ii) is it effective in reducing the nasal carriage of pathogen (Staphylococcus aureus) in humans.

NCT ID: NCT01746108 Completed - Clinical trials for Infections, Streptococcal

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection

Start date: June 18, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10Pn-PD-DiT vaccine in children aged between 2 and 17 years of age having asplenia, splenic dysfunction or complement deficiencies. In addition, this study will include an age-matched control group of healthy children aged 24-59 months in order to descriptively compare the immunogenicity of 10Pn-PD-DiT vaccine in the at-risk population to that of the general, healthy population one month after each pneumococcal vaccination.

NCT ID: NCT01745328 Recruiting - Clinical trials for Recurrent Urinary Tract Infection

Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine

Start date: January 2009
Phase: N/A
Study type: Interventional

Traditional Chinese Medicine (TCM) could be used to treat Recurrent urinary tract infection (RUTI).

NCT ID: NCT01741649 Completed - Clinical trials for Surgical Wound Infection

Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section

Start date: October 2012
Phase: N/A
Study type: Interventional

Many solutions are used for cleaning the skin of a patient previous to a surgery. Although the efficacy of clorhexidine has been proved in other surgical procedures, there is only a retrospective study in cesarean section (they report no benefit of one solution over the other). The investigators would like to evaluate the difference in surgical site infection in patients after cesarean section comparing preparation of the skin with clorhexidine versus povidone.